Salivary Oxytocin as a Biomarker of Psychedelic Treatment

Enrolling by invitation

Conditions studied: Major Depressive Disorder (MDD)

In brief

This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.

Key facts

Study ID

NCT07345858

Run by

University of Geneva, Switzerland

People needed

80

Starts

2026-01-05

Expected to finish

2026-10-30

Last updated by the study team

2026-01-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >=18 years-old
• MDD defined by DSM-V criteria, and resistant to treatment
• Ongoing classical psychotherapeutic treatment
• Agreement to discontinue necessary psychotropic medications (some classes of anti-depressants are allowed with no need to taper off).

You may not qualify if…

• Psychotic or bipolar disorder
• High suicidal risk
• Severe cardiovascular, hepatic or neurological (affecting the central nervous system) disorders
• Pregnancy or breastfeeding.

Where it is running

• Geneva University Hospitals — Geneva, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.